|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In these cells, we also determined the efficacy of triphenyl-phosphonium-carboxy-proxyl (Mito-CP) because this mitochondria-targeted metabolism interfering agent exhibited similar tumor suppressive effects as mortalin depletion in MTC cells.
|
31027376 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mortalin levels were sequentially increased in serous benign, borderline and carcinoma tumors.
|
31845320 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinically, high Mortalin expression correlated with malignant phenotype of HCC, such as microvascular invasion (<i>p</i>=0.017) and tumor diameter (<i>p</i>=0.001).
|
31772652 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mortalin-2 (mot-2) is a dominant oncoprotein in several tumors, including colorectal cancer (CRC).
|
30107089 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mortalin expression in tumour samples from patients with ICC was examined by Western blot and immunohistochemistry, and correlation between its expression and clinicopathological features was assessed.
|
28096273 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in <i>KRAS</i> and <i>BRAF</i> Tumor Cells.
|
28674184 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This current study determines whether UBXN2A effectively binds to and occupies mortalin's binding pocket, resulting in a direct improvement in the tumor's sensitivity to chemotherapy.
|
26634371 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bioinformatic analysis of tumor transcriptomic data revealed regulatory gene networks and highlighted mortalin and moesin as master regulators while gene reporter and ChIP assays in the H1299 lung cancer cell line as well as cross-examination of published ChIP-sequence data of 7 human and 2 mouse cell lines provided strong evidence for the identified genes to be c-Myc targets.
|
26427040 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, compared with the full-length mortalin overexpressing cancer cells, mot-N derivatives showed increased malignant properties, including higher proliferation rate, colony forming efficacy, motility, and tumor forming capacity both in in vitro and in vivo assays.
|
25012652 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, in tumors with normal p53 function, mortalin-positive tumors had worse prognosis compared with mortalin-negative tumors (P = 0.017).
|
23828548 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant positive correlation was found between the expression of Mortalin and Vimentin, and tumors with high expression of Mortalin had a tendency to higher MVD compared to those with low expression of Mortalin.
|
24190572 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
More intriguingly, the level of GRP75/RARα/RXRα tripartite complexes was tightly associated with the RA-induced suppression of tumor growth in animals and the histological grade of differentiation in human NB tumors.
|
22022577 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Through immunohistochemistry we showed that mortalin was significantly higher in tumors than in adjacent benign tissues.
|
21714113 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mortalin (HSPA9) is associated with HCC metastasis and thus suggested as a tumor marker for predicting early recurrence, which may have immediate clinical applications for cancer surveillance after curative surgery.
|
17934217 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HSPA9 was recently localized to chromosome 5, band q31, a region that is frequently deleted in myeloid leukemias and myelodysplasia (MDS), making it a candidate tumor suppressor gene, which is consistent with the biological function of its murine homologue.
|
11187902 |
2000 |